Evidence map›Paper›PMID 38369951›Full record

Trial reportClinical pharmacology and therapeutics2024

Genetic Prediction of Smoking Cessation Medication Side Effects: A Genome-Wide Investigation of Abnormal Dreams on Varenicline.

Meghan J Chenoweth, Yong Jae Kim, Nikki L Nollen, Larry W Hawk, Martin C Mahoney, Caryn Lerman, Jo Knight, Rachel F Tyndale

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical pharmacology and therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01314001 (Pharmacogenetics of Nicotine Addiction Treatment), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01314001 phase3completednot on this map

Pharmacogenetics of Nicotine Addiction Treatment (PNAT)

TypeinterventionalSponsorUniversity of PennsylvaniaRan2010 to 2014Enrolled1,246ConditionsNicotine AddictionArmsVarenicline, Placebo, Transdermal Nicotine
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Meghan J ChenowethCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.ORCID 0000-0002-8218-8240
Yong Jae KimDepartment of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Nikki L NollenDepartment of Population Health, University of Kansas School of Medicine, Kansas City, Kansas, USA.
Larry W HawkDepartment of Psychology, University at Buffalo, Buffalo, New York, USA.ORCID 0000-0001-6593-9746
Martin C MahoneyDepartment of Internal Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Caryn LermanUSC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Jo KnightDepartment of Psychiatry, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-7148-1660
Rachel F TyndaleCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.ORCID 0000-0003-1297-2053
Centre for Addiction and Mental Health · CAUniversity of Toronto · CARoswell Park Comprehensive Cancer Center · USUniversity at Buffalo, State University of New York · USUniversity of Kansas · USUniversity of Southern California · US

Funding

University of Toronto Coordinating Genetics Core & Clinical Trial SiteU01DA020830 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI BENOWITZ, NEAL L · 2005 to 2014
$22.4M
Neuroscience-based Interventions for Cancer Risk Behavior ChangeR35CA197461 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LERMAN, CARYN · 2015 to 2021
$6.0M
EVarQuit: Extinguishing cigarette smoking via extended pre-quit vareniclineR01CA206193 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI HAWK, LARRY W, MAHONEY, MARTIN CHRISTOPHER · 2017 to 2021
$3.7M
Understanding Disparities in Quitting in African American and White SmokersR01DA031815 · NIDA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI NOLLEN, NICOLE L · 2012 to 2016
$3.2M
NCI NIH HHS R01 CA206193NCI NIH HHS R35 CA197461NIDA NIH HHS R01 DA031815NIDA NIH HHS U01 DA020830
6 · The paper itself

Abstract

Varenicline, the most efficacious smoking cessation monotherapy, produces abnormal dreams. Although genetic contributions to varenicline-associated nausea and cessation have been identified, the role of genetics in abnormal dreams is unknown. We conducted a genomewide association study (GWAS) of abnormal dreams in 188 European ancestry smokers treated with varenicline (NCT01314001). Additive genetic models examined the likelihood of experiencing abnormal dreams 2 weeks following varenicline initiation. For the top locus, we tested for selectivity to varenicline, effects on cessation, replication, and generalizability to African ancestry (AA) individuals. The top GWAS variant associated with abnormal dreams was rs901886, mapping to intron 2 of ICAM5 on chromosome 19. The prevalence of abnormal dreams in those with rs901886 CC, CT, and TT genotypes was 15%, 36%, and 62%, respectively (odds ratio = 2.94 for T vs. C, 95% confidence interval = 1.92-4.55, P = 2.03e

Indexed as

DreamsGenome-Wide Association StudySmoking CessationSmoking Cessation AgentsVareniclineAdultFemaleHumansMaleMiddle AgedPolymorphism, Single NucleotideSmoking Cessation AgentsVarenicline

Identifiers

PMID38369951
PMCPMC13035048
OpenAlexW4391931994

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.